MedPath

Study of effectiveness of a skin whitening cream on 40 adult female volunteers for 6 weeks

Not Applicable
Completed
Registration Number
CTRI/2013/02/003426
Lead Sponsor
The Himalaya Drug Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
46
Inclusion Criteria

Female subjects

-Age: 18 to 55 years; both inclusive

-A subject having given written consent of her free, informed and specific willingness to participate

-Subjects having skin phototype III, IV and V

-Subjects having dark spots, freckles, pigmented

demarcation lines, and uneven tone

-Subjects having under-eye dark circles with a

score >=2

-Subjects having visible fine lines on face

-A subject having good physical health as

determined by the Investigator

-A cooperative subject informed of the importance

and the duration of the controls, enabling complete respect of the protocols established by the Clinical Centre

-Female participants must have a negative

pregnancy test at screening visit and willing to use acceptable contraceptive measures during the study

Exclusion Criteria

-Female subject who is pregnant or breast-feeding

(or planning to get pregnant during the study)

-A known history or present condition of allergic

response to any cosmetic products

-Subject having skin diseases (e.g. moderate to

severe acne vulgaris on face or nodulocystic acne,

psoriasis, active atopic dermatitis, pigmented

contact dermatitis or other cutaneous

manifestations), which can interfere with the test

readings

-Subjects taking oral contraceptive or any hormonal treatment since less than 1.5 month

-Any treatment, topical or systemic, taken in the

weeks preceding the test, which is likely to

interfere with the evaluation of the efficacy of the product(s) being studied

-Subjects undergoing anti-inflammatory, corticoids

or retinoids therapy by oral way

Subject having used depigmenting products, masks

exfoliant product on the studied zone in last 4

weeks

-Excessive exposure to sunlight (sun bathing,

swimming, prolong sun exposure) or UV-rays

within the previous month and during the study

-Subject who has been deemed by the investigator

as potentially unable or unwilling to comply with

the protocol

-Subject enrolled in another clinical trial during the study period

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the skin whitening effects of a cosmetic product for: <br/ ><br>- Reduction in dark spots and skin blemishes <br/ ><br>- Reduction of under eye dark circles <br/ ><br>- Reduction in excessive sebum secretion <br/ ><br>- Reduction in fine lines on face <br/ ><br>- Enhancement of facial skin tone, as illustrated by a shade card assessmentTimepoint: Day 0, Day 14, Day 28, Day 42
Secondary Outcome Measures
NameTimeMethod
Measurement of skin hydration effects by CorneometerTimepoint: Day 0, 14, 28, 42;Subjective evaluation questionnaireTimepoint: Day 14, 28, 42
© Copyright 2025. All Rights Reserved by MedPath